Back to Search
Start Over
A randomized, blinded, multicenter trial of a gentamicin vancomycin gel (DFA-02) in patients undergoing abdominal surgery.
- Source :
-
American journal of surgery [Am J Surg] 2017 Jun; Vol. 213 (6), pp. 1003-1009. Date of Electronic Publication: 2016 Nov 18. - Publication Year :
- 2017
-
Abstract
- Background: SI is a significant medical problem. DFA-02 is an investigational bioresorbable modified release gel consisting of both gentamicin (16.8 mg/mL) and vancomycin (18.8 mg/mL). A Phase 2a study, where the drug was applied during surgical incision closure, suggested safety and tolerability but was not designed to assess its efficacy.<br />Study Design: In a Phase 2b randomized, blinded trial patients undergoing abdominal, primarily colorectal, surgery were randomized (4:1:1) to one of three study arms: DFA-02, matching placebo gel, or standard of care (SOC) involving irrigation of the wound with normal saline. The DFA-02 and placebo gel groups received up to 20 mL of study drug inserted above the fascia during wound closure, and were treated in a double-blind manner; the SOC group was treated in a single-blind manner. The primary endpoint was SSI (adjudicated centrally by a blinded committee) through postoperative day 30.<br />Results: Overall, 445 subjects (intention-to-treat) were randomized at 35 centers with 425 subjects completing the study and being evaluable. There were 67 SSIs (15.8%): 64.2% superficial, 7.5% deep, and 28.4% organ space. The incidence of SSI was not statistically significantly different between the DFA-02 and the placebo gel/SOC arms combined, 42/287 = 14.6% vs 25/138 = 18.1% (p = 0.36), respectively. Rehospitalization within 30 days was also similar between study groups (DFA-02 28.6%, placebo gel 21.4%, SOC 27.3%).<br />Conclusion: In this multicenter, blinded, randomized trial with central adjudication, the gentamicin/vancomycin gel was not associated with a significant reduction in SSI.<br />Summary: Patients undergoing abdominal surgery were randomized to one of three study arms: DFA-02 gel consisting of both gentamicin and vancomycin, matching placebo gel, or standard of care (SOC). Of 425 patients completing the study at 35 sites the gentamicin/vancomycin gel was not associated with a significant reduction in SSI.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Double-Blind Method
Female
Gels
Humans
Incidence
Male
Middle Aged
Single-Blind Method
Surgical Wound Infection epidemiology
Treatment Outcome
Abdominal Wound Closure Techniques
Anti-Bacterial Agents therapeutic use
Digestive System Surgical Procedures adverse effects
Gentamicins therapeutic use
Surgical Wound Infection prevention & control
Vancomycin therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1879-1883
- Volume :
- 213
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- American journal of surgery
- Publication Type :
- Academic Journal
- Accession number :
- 27989501
- Full Text :
- https://doi.org/10.1016/j.amjsurg.2016.10.007